Bayer Pharmaceuticals Corporation

Avelox benefits study patients with community-acquired pneumonia

Published in Physician Law Weekly, June 2nd, 2004

A study presented at the 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) showed that hospitalized patients with community-acquired pneumonia (CAP) who received sequential therapy with the intravenous (IV) and oral forms of the antibiotic Avelox (moxifloxacin HCl) experienced faster symptom improvement and earlier hospital discharge than patients treated with the antibiotic ceftriaxone.

"This study also showed how switching to oral antibiotic therapy as soon as CAP patients are clinically stable can reduce their hospital stay and possibly lower associated costs," said Michael Niederman, MD, Winthrop University Hospital, Mineola,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Physician Law Weekly

Source: Physician Law Weekly (2004-06-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry